Press Release: Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease
BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today presented positive Phase 2 results of solengepras, a novel, non-dopaminergic GPR6 inhibitor in development as an adjunctive treatment for Parkinson’s disease. The findings demonstrated that four weeks of once-daily treatment with solengepras significantly reduced…
SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Freeport-McMoRan Inc. (NYSE: FCX) publicly traded securities between February 15, 2022 and September 24, 2025, inclusive (the “Class Period”), have until Monday, January 12, 2026 to seek appointment as lead plaintiff of the Freeport-McMoRan class…
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Synopsys, Inc. (NASDAQ: SNPS) between December 4, 2024 and September 9, 2025, both dates inclusive (the “Class Period”), of the important December 30, 2025 lead plaintiff deadline.
MANHATTAN, Kan., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Rally House is fired up to celebrate a monumental moment in Kansas State University athletics: the hiring of Collin Klein as the new Head Coach of the Wildcats. As a former Heisman finalist, All-American, and one of the most beloved quarterbacks in K-State history, Klein’s return to…
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The Mexico Equity and Income Fund, Inc. (NYSE: MXE) (the “Fund”) today announced that the Fund’s Board of Directors has declared a year-end cash dividend of $0.2337 per share on its common stock consisting entirely of ordinary income payable on December 31, 2025 to stockholders of record…
